The Protective Immune Response against Infectious Bronchitis Virus Induced by Multi-Epitope Based Peptide Vaccines

Tai, Yang; Wang, Hongning; Wang, Xue; Tang, Junni; Lu, Dan; Zhang, Yun‐Fei; Z, Guo; Li, Yuling; Gao, Rong; Kang, Ran

doi:10.1271/bbb.80864

Cited by 33 publications

(29 citation statements)

References 35 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, there is an urgent need to develop new, safe and effective vaccines to control the disease. Recombinant subunit vaccines have been shown to elicit strong humoral and cellular immune responses and be very safe [16][17][18]. Therefore subunit vaccines may serve as potential vaccine candidates in the future.…”

Section: Discussionmentioning

confidence: 99%

“…Among new vaccines, subunit vaccines have been showed to elicit strong humoral and cellular immune responses [16][17][18]. Subunit vaccines have significant advantages of efficient antigenic presentation, high stability, and flexibility in proteins or epitopes selection compared with live-attenuated and inactivated vaccines [16].…”

Section: Introductionmentioning

confidence: 99%

“…Subunit vaccines have significant advantages of efficient antigenic presentation, high stability, and flexibility in proteins or epitopes selection compared with live-attenuated and inactivated vaccines [16]. In addition, no infectious viral particles are involved in the course of vaccine production, so they are very safe.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Greater Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by Recombinant Baculovirus Co-expressing S1 and N Proteins

Yuan¹,

Zhang²,

He³

et al. 2018

Preprint

View full text Add to dashboard Cite

Avian infectious bronchitis virus (IBV) is the causative agent of infectious bronchitis, which causes considerable economic losses to the poultry industry worldwide. It is imperative to develop safe and efficient candidate vaccines to control IBV infection. In the current study, recombinant baculoviruses co-expressing S1 and N proteins, mono-expressing S1 or N proteins alone of IBV were constructed and prepared into subunit vaccines rHBM-S1-N, rHBM-S1 and rHBM-N. The levels of immune protection of these subunit vaccines were evaluated by inoculating specific pathogen-free (SPF) chickens at 14 days of age, boosting with the same dose 14 days later, and following challenge with a virulent GX-YL5 strain of IBV 14 days post-booster (dpb). The commercial vaccine strain H120 was used as a control. The IBV-specific antibody levels as well as the percentages of CD4+ and CD8+ T lymphocytes were detected within 28 days post-vaccination (dpv). The morbidity, mortality, and re-isolation of virus from the tracheas and kidneys of challenged birds were evaluated at 5 days post-challenge (dpc). The results showed that the IBV-specific antibody levels and the percentages of CD4+ and CD8+ T lymphocyte in rHBM-S1-N group were higher than those of rHBM-S1 and rHBM-N groups, especially the cellular immunity response. At 5 dpc, the mortality, morbidity and virus re-isolation rate of rHBM-S1-N were slightly higher than those of H120 group, but were lower than those of rHBM-S1 group and rHBM-N group. The present study demonstrated that the protection of recombinant baculovirus co-expressing S1 and N proteins was better than that of recombinant baculoviruses mono-expressing S1 or N protein alone. Thus, the recombinant baculovirus co-expressing S1 and N proteins could serve as a potential IBV vaccine and this demonstrates that the bivalent subunit vaccine including the S1 and N proteins might be a strategy for the development of an IBV subunit vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Greater Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by Recombinant Baculovirus Co-expressing S1 and N Proteins

Yuan¹,

Zhang²,

He³

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…The individual mimotope was linked by GSGGS with the sequence SIV7-SIV12-H1N17-H1N112-H3N27-H3N212-H2N27-H2N212, which was used to test whether the synthetic gene with multiple GSGGS inserting affected the expression. The synthetic gene with multiple GSGGS was expressed successfully in E. coli , which was confirmed by SDS-PAGE [33]. …”

Section: Discussionmentioning

confidence: 99%

Mimotopes selected with neutralizing antibodies against multiple subtypes of influenza A

Zhong

Cai

Zhang

et al. 2011

Virol J

View full text Add to dashboard Cite

BackgroundThe mimotopes of viruses are considered as the good targets for vaccine design. We prepared mimotopes against multiple subtypes of influenza A and evaluate their immune responses in flu virus challenged Balb/c mice.MethodsThe mimotopes of influenza A including pandemic H1N1, H3N2, H2N2 and H1N1 swine-origin influenza virus were screened by peptide phage display libraries, respectively. These mimotopes were engineered in one protein as multi- epitopes in Escherichia coli (E. coli) and purified. Balb/c mice were immunized using the multi-mimotopes protein and specific antibody responses were analyzed using hemagglutination inhibition (HI) assay and enzyme-linked immunosorbent assay (ELISA). The lung inflammation level was evaluated by hematoxylin and eosin (HE).ResultsLinear heptopeptide and dodecapeptide mimotopes were obtained for these influenza virus. The recombinant multi-mimotopes protein was a 73 kDa fusion protein. Comparing immunized infected groups with unimmunized infected subsets, significant differences were observed in the body weight loss and survival rate. The antiserum contained higher HI Ab titer against H1N1 virus and the lung inflammation level were significantly decreased in immunized infected groups.ConclusionsPhage-displayed mimotopes against multiple subtypes of influenza A were accessible to the mouse immune system and triggered a humoral response to above virus.

show abstract

“…Other groups also have reported that immunization with recombinant S1 http://dx.doi.org/10.1016/j.virusres.2015.06.019 0168-1702/© 2015 Elsevier B.V. All rights reserved. epitope peptide expressed from Escherichia coli (E. coli) protected chickens against IBV infection (Yang et al, 2009a(Yang et al, , 2009b. Furthermore, viral vectored vaccines co-expressing the S1 protein and host cytokines have been reported to induce anti-S1 antibodies (Chen et al, 2010;Shi et al, 2011;Tomley et al, 1987;Wang et al, 2009;Zeshan et al, 2011;Zhang et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Decreased neutralizing antigenicity in IBV S1 protein expressed from mammalian cells

et al. 2015

View full text Add to dashboard Cite

We evaluated the antigenicity of recombinant infectious bronchitis virus (IBV) S1 protein expressed in mammalian cells. Recombinant S1 was expressed as a secreted protein fused with a trimerization motif peptide, then purified using Ni Sepharose. The purified protein was analyzed by Western blotting, mixed with oil adjuvant, and administered to 29-day-old specific-pathogen-free chickens. Six weeks after immunization, anti-IBV neutralizing titer and anti-S1 ELISA titer were determined; immunized chickens then were inoculated with IBV via the trachea and ciliary activity was observed. Results showed that the recombinant S1 protein was highly glycosylated, and the neutralizing antigenicity of recombinant S1 protein was lower than that of inactivated virus. However, anti-S1 ELISA indicated that the recombinant S1 protein induced antibodies against S1. These results suggest that the recombinant S1 may retain non-neutralizing epitopes but have unnatural glycosylation pattern and conformation, resulting in lacking neutralizing conformational epitopes. In conclusion, the neutralizing antigenicity of recombinant S1 protein expressed from mammalian cells was decreased, and was not sufficient to induce neutralizing antibodies.

show abstract

The Protective Immune Response against Infectious Bronchitis Virus Induced by Multi-Epitope Based Peptide Vaccines

Cited by 33 publications

References 35 publications

Greater Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by Recombinant Baculovirus Co-expressing S1 and N Proteins

Greater Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by Recombinant Baculovirus Co-expressing S1 and N Proteins

Mimotopes selected with neutralizing antibodies against multiple subtypes of influenza A

Decreased neutralizing antigenicity in IBV S1 protein expressed from mammalian cells

Contact Info

Product

Resources

About